STOCK TITAN
  1. Home
  2. Sec-filings
  3. TMO
  4. [8-K] Thermo Fisher Scientific, Inc. Reports Material Event

Thermo Fisher (NYSE: TMO) completes Solventum purification and filtration acquisition

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Thermo Fisher Scientific Inc. has completed its acquisition of Solventum Corporation’s purification and filtration business. The company announced the closing in a press release dated September 2, 2025, following the earliest event date of September 1, 2025.

The acquired operations focus on purification and filtration technologies, which fit within Thermo Fisher’s broader scientific and laboratory solutions portfolio. Details such as purchase price, financing, and expected financial impact are not included in this summary document but are referenced in the attached press release.

Positive

  • None.

Negative

  • None.

Insights

Thermo Fisher closes targeted deal for Solventum’s purification and filtration unit.

Thermo Fisher Scientific discloses that it has completed acquiring Solventum Corporation’s purification and filtration business. This adds a specialized set of purification and filtration products and capabilities to Thermo Fisher’s existing scientific tools and services franchise, reinforcing its role as a consolidator in life science tools.

The excerpt does not quantify the size of the acquired business, the purchase consideration, or expected synergies, so the financial impact cannot be assessed from this text alone. However, the transaction is presented as fully closed as of early September 2025, not merely agreed.

Further detail on integration plans, revenue contribution, and cost structure is referenced as being in a 99.1 press release dated September 2, 2025. Subsequent periodic reports may outline how this purification and filtration business affects segment performance and margins once it is folded into Thermo Fisher’s operating results.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What transaction did Thermo Fisher Scientific (TMO) disclose in this 8-K?
Thermo Fisher Scientific disclosed that it completed the acquisition of Solventum Corporation’s purification and filtration business. The company reported that closing of this deal was announced in a press release dated September 2, 2025, attached as Exhibit 99.1 for additional detail.

When did Thermo Fisher complete the Solventum purification and filtration acquisition?
Thermo Fisher links the transaction to an earliest event date of September 1, 2025, and issued a press release on September 2, 2025 announcing completion. The 8-K confirms the deal is closed rather than pending, referencing that press release as Exhibit 99.1.

What business did Solventum sell to Thermo Fisher Scientific (TMO)?
Solventum Corporation sold its purification and filtration business to Thermo Fisher Scientific. The description in the disclosure indicates this unit focuses on purification and filtration technologies, which align with Thermo Fisher’s scientific and laboratory solutions offerings across research, diagnostics, and manufacturing workflows.

Where can investors find more details on Thermo Fisher’s Solventum deal?
More details are provided in Thermo Fisher’s press release attached as Exhibit 99.1, dated September 2, 2025. The 8-K states this press release is incorporated by reference, meaning it forms part of the official disclosure about the completed acquisition.

Does the Thermo Fisher 8-K state that the Solventum transaction is fully closed?
Yes. Thermo Fisher states that it issued a press release announcing the completion of its acquisition of Solventum Corporation’s purification and filtration business. The language describes the acquisition as completed, not conditional or pending, as of early September 2025.
0000097745FALSE00000977452025-09-012025-09-010000097745us-gaap:CommonStockMember2025-09-012025-09-010000097745tmo:SeniorNotes3200Due2026Member2025-09-012025-09-010000097745tmo:SeniorNotes1.40Due2026Member2025-09-012025-09-010000097745tmo:A1.45SeniorNotesDue2027Member2025-09-012025-09-010000097745tmo:SeniorNotes175Due2027Member2025-09-012025-09-010000097745tmo:SeniorNotes0.500Due2028Member2025-09-012025-09-010000097745tmo:SeniorNotes1.375Due2028Member2025-09-012025-09-010000097745tmo:SeniorNotes1.95Due2029Member2025-09-012025-09-010000097745tmo:SeniorNotes0.875Due2031Member2025-09-012025-09-010000097745tmo:SeniorNotes2375Due2032Member2025-09-012025-09-010000097745tmo:SeniorNotes3650Due2034Member2025-09-012025-09-010000097745tmo:SeniorNotes2.875Due2037Member2025-09-012025-09-010000097745tmo:SeniorNotes1.500Due2039Member2025-09-012025-09-010000097745tmo:SeniorNotes1.875Due2049Member2025-09-012025-09-01



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 1, 2025

THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its Charter)
Delaware1-800204-2209186
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 622-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $1.00 par valueTMONew York Stock Exchange
3.200% Notes due 2026TMO 26BNew York Stock Exchange
1.400% Notes due 2026TMO 26ANew York Stock Exchange
1.450% Notes due 2027TMO 27New York Stock Exchange
1.750% Notes due 2027TMO 27BNew York Stock Exchange
0.500% Notes due 2028TMO 28ANew York Stock Exchange
1.375% Notes due 2028TMO 28New York Stock Exchange
1.950% Notes due 2029TMO 29New York Stock Exchange
0.875% Notes due 2031TMO 31New York Stock Exchange
2.375% Notes due 2032TMO 32New York Stock Exchange
3.650% Notes due 2034TMO 34New York Stock Exchange
2.875% Notes due 2037TMO 37New York Stock Exchange
1.500% Notes due 2039TMO 39New York Stock Exchange
1.875% Notes due 2049TMO 49New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐





Item 8.01    Other Events.

On September 2, 2025, Thermo Fisher Scientific Inc. (“Thermo Fisher”) issued a press release announcing the completion of its acquisition of Solventum Corporation’s purification and filtration business. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits

99.1    Press Release of Thermo Fisher Scientific Inc., dated September 2, 2025.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)



2




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THERMO FISHER SCIENTIFIC INC.
Date:September 2, 2025By:/s/ Thomas B. Shropshire
Thomas B. Shropshire
Senior Vice President and General Counsel

3

Source: View Original Filing on SEC EDGAR